Arcus Biosciences Inc.
13.79
-0.14 (-1.01%)
At close: Jan 14, 2025, 3:59 PM
13.82
0.25%
After-hours Jan 14, 2025, 07:00 PM EST
undefined%
Bid 13.73
Market Cap 1.26B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.13
PE Ratio (ttm) -4.4
Forward PE n/a
Analyst Buy
Ask 14.95
Volume 418,215
Avg. Volume (20D) 742,937
Open 14.02
Previous Close 13.93
Day's Range 13.65 - 14.13
52-Week Range 13.51 - 20.31
Beta undefined

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Pha...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 15, 2018
Employees 577
Stock Exchange NYSE
Ticker Symbol RCUS

Analyst Forecast

According to 10 analyst ratings, the average rating for RCUS stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 117.63% from the latest price.

Buy 80.00%
Hold 20.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Arcus Biosciences Inc. is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of $31.31M, reflecting a 1.00% YoY growth and earnings per share of -1.2, making a 11.11% increase YoY.
2 months ago · Source
+2.89%
Arcus Biosciences shares are trading higher after ... Unlock content with Pro Subscription
2 months ago · Source
-7.97%
Arcus Biosciences shares are trading lower. HC Wainwright & Co. initiated coverage on the stock with a Neutral rating and announced a price target of $20.